Tissue engineered mimetic periosteum for efficient delivery of rhBMP-2

Tools

Romero-Torrecilla, Juan Antonio and Muinos-Lopez, Emma and Valdés-Fernández, José and López-Martínez, Tania and Ripalda-Cemboráin, Purificación and Jayawarna, Vineetha and Childs, Peter and Salmeron-Sanchez, Manuel and Prósper, Felipe and Granero-Moltó, Froilán (2022) Tissue engineered mimetic periosteum for efficient delivery of rhBMP-2. Bone Reports, 16 (Supple). 101252. ISSN 2352-1872 (https://doi.org/10.1016/j.bonr.2022.101252)

[thumbnail of Romero-Torrecilla-etal-BR-2022-Tissue-engineered-mimetic-periosteum-for-efficient]
Preview
 Text. Filename: Romero_Torrecilla_etal_BR_2022_Tissue_engineered_mimetic_periosteum_for_efficient.pdf
Final Published Version
License: Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 logo
Download (747kB)| Preview

Abstract

Background: Despite its unique regenerative capacity, bone healing can be compromised, leading to delayed fracture regeneration and consequently nonunion. Due to the scarcity of autografts and the problems associated with a supraphysiological use of rhBMP-2, novel tissue engineering strategies arise as a promising solution to overcome nonunions and related bone pathologies. Purpose: To clinically deal with fracture nonunion, we designed engineered mimetic autografts consisting of a personalized polycaprolactone (PCL) scaffold surrounded by a porous PCL membrane mimicking the periosteum synthesized by melt electrowriting (MEW) (Figure 1). Methods: MEW membrane was functionalized with poly ethyl acrylate (PEA) and Fibronectin for efficient rhBMP-2 binding and delivery. The regenerative capacity and therapeutic potential of these scaffolds were tested in vitro for osteoblast differentiation and vivo in a critical size femur defect in Sprague Dawley rats (n=6-7 animals/group) (ethical approval 073-20). Regenerative effects were assessed by qPCR, q-mCT and histological analysis. Non-parametric Kruskal Wallis test was used for statistical analysis. Results: We selected the two lowest dose implants (10 mg/ml, 51.94±8.84 ng and 25 mg/ml, 186.8±17.33) to assess release profile over time and for in vivo therapeutic effect. In vitro, single loading of 186 ng of rhBMP-2 allows similar differentiation potential that standard osteogenic differentiation medium where fresh rhBMP-2 was added twice weekly (Figure 2). In vivo, regarding bone regeneration, quantitative μCT analysis shows great bone healing of defects treated with rhBMP-2 at concentrations of 25 μg/ml (186 ng) and 10 μg/ml (52 ng). Control group, 6.80±2.47 mm3; 10 μg/ml BMP-2 group 19.53±4.266 mm3, *p=0.0324; 25 μg/ml BMP-2 group 24.48±11.30 mm3, **p=0.0087. In addition, histological analysis was carried out to determine the osteoconductive potential of our PCL core (Figure 3). Conclusion: In conclusion, PEA functionalized mimetic periosteum show an unpreceded increase in bone healing, greatly enhancing rhBMP-2 effects.

ORCID iDs

Romero-Torrecilla, Juan Antonio, Muinos-Lopez, Emma, Valdés-Fernández, José, López-Martínez, Tania, Ripalda-Cemboráin, Purificación, Jayawarna, Vineetha, Childs, Peter ORCID logoORCID: https://orcid.org/0000-0001-7603-9911, Salmeron-Sanchez, Manuel, Prósper, Felipe and Granero-Moltó, Froilán;
CORE (COnnecting REpositories)